Eli Lilly's Alzheimer's drug falls short for accelerated approval from the FDA
.png)
Eli Lilly's Alzheimer's drug donanemab is rejected for accelerated approval by the US FDA, but the clinical trial data still shows promise for coming up for standard approval later in the year.
The much anticipated ruling from the US FDA on Eli Lilly’s Alzheimer’s drug has been released, with the regulators rejecting the application for accelerated approval of donanemab.
The FDA explained its rejection of the experimental drug from Eli Lilly was due to a lack of trial data from patients who had been treated with the drug for a minimum of one year.
The drug, donanemab, is a humanised monoclonal antibody that actively removes amyloid plaques from the brains of those with early-stage Alzheimer’s disease. There has been some concern over using these antibodies in patients as they can cause microhaemorrhages in the brain, but this hasn’t been shown when donanemab has been tested. However, the FDA have noted that not enough trial data exists for them to fully rule out any concerns.
Eli Lilly received a complete response letter from the FDA regarding donanemab, which is likely to stipulate the standards that need to be met for the drug to be approved.
The FDA had issued the letter "due to the limited number of patients with at least 12 months of drug exposure data provided in the submission," Eli Lilly stated.
Lilly points out that patients in the mid-stage trial who achieved clearance of the amyloid plaques in their brains then stopped the treatment. This typically took around six months in 40% of patients.
"I don't think it says anything negative about the drug. It was just a manifestation of the study design," commented Dr Ronald Petersen, an Alzheimer's expert at the Mayo Clinic in Rochester, MN, USA.
The drug is still undergoing a Phase III trial to further confirm results, with this data hopefully supporting the current information, which altogether will be used in the next application for FDA approval later in the year.
"I don't see this is an impediment to the process or timeline in any way," remarked Dr Eric Reiman, Executive Director of Banner Alzheimer's Institute. "When the Phase III trial reads out, I understand it will have that safety data in at least 100 people."
Chief Operating Officer Russ Paulsen from UsAgainstAlzheimer's stated that the advocacy group was "disappointed this treatment won’t be made available to patients sooner," but was encouraged by the reason. "Donanemab worked too well... The FDA requires a minimum of 100 patients to be on the drug for at least 12 months but, due to donanemab's quick action in some patients, many were able to stop treatment in as little as six months," he put in an email.
The nuance of accelerated approval from the US FDA means that approval can only be granted if the measurement of an indicator correlates directly to an improvement in patient response and outcomes. Therefore longer-term clinical data is necessary to fully evaluate the patient outcomes.
Related News
-
News Merck invests US$1 billion in new USA-based vaccine facility
Merck annouces the opening of a new state-of-the-art vaccine production plant in Durham, North Carolina, USA, in efforts to bring pharmaceutical product development onto home soil in face of new import tariffs. -
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News The next 15 drugs up for negotiation with Medicare include several blockbusters
By now, everyone is quite familiar with the drug price negotiations taking place between drug companies and the Centres for Medicare & Medicaid Services (CMS) in the USA as part of measures being taken to reduce the cost of drugs for patients, to make ... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Trump's federal funding shift could stifle biotech innovation
Over a month into the second term of Donald Trump’s presidency and we have already seen some big changes affecting the healthcare industry. -
News Sanofi receives FDA warning over contamination at manufacturing site
The FDA issues a warning letter to Sanofi over contamination violations found at the Framingham biologics facility, in Boston, MA, USA.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance